Why This Hims Analyst Sees Strong Growth Potential In Highly Competitive Market

The potential for expansion coupled with a highly competitive pharmacy market has a BofA Securities analyst sidelined on shares of Hims & Hers Health, Inc. HIMS.

The Hims Analyst: Michael Cherny initiated coverage on shares of Hims & Hers Health, Inc. with a Neutral rating and $12 price target. 

The Hims Takeaways: Hims has strong growth potential, but the company operates in a “highly competitive market with multiple well-established incumbents,” painting the risk-reward potential as balanced, Cherny said in a Tuesday note.

Despite only launching in a few categories, Hims has seen a strong start in the rollout of its tech-enabled pharmacy solutions, which “provides a meaningful upside opportunity for market expansion,” the analyst said.

Regarding market share, the company’s total addressable market sits at $65 billion, and its targeted areas for growth should add an estimated $120 billion to that figure, he said.

These targeted areas all have a chronic need, generating recurring revenue, as the majority of Hims offerings do, Cherny said.

The company also has a net promoter score of 65, “far outpacing many other tech-enabled industries,” which should set the company up for future customer acquisition, the analyst said. 

The $12 price target is derived from an 8.5x multiple on CY2022 EV/revenue, reflecting the company’s high margins, strong growth potential and nascent nature, according to BofA. 

HIMS Price Action: Shares of Hims & Hers Health, Inc. were up 2.65% at $10.65 at last check Tuesday. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetInitiationAnalyst RatingsBofA SecuritiesMichael Cherny
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!